Front. Nephrol. Frontiers in Nephrology Front. Nephrol. 2813-0626 Frontiers Media S.A. 10.3389/fneph.2022.1129134 Nephrology Correction Corrigendum: Cemiplimab for advanced cutaneous squamous cell carcinoma in kidney transplant recipients Van Meerhaeghe T. 1 * Baurain J.F. 2 Bechter O. 3 Orte Cano C. 4 Del Marmol V. 4 Devresse A. 5 Doubel P. 6 Hanssens M. 7 Hellemans R. 8 Lienard D. 4 Rutten A. 9 Sprangers B. 10 Le Moine A. 1 Aspeslagh S. 11 1 Department of Nephrology, Hôpital Erasme – Université Libre de Bruxelles (ULB), Brussels, Belgium 2 Department of Oncology, Clinique Universitaire Saint-Luc – Université Catholique de Louvain (UCLouvain), Brussels, Belgium 3 Department of Oncology, Universitair Ziekenhuis (UZ) Leuven – Katholieke Universiteit Leuven (KUL), Leuven, Belgium 4 Department of Dermatology, Hôpital Erasme – Université Libre de Bruxelles (ULB), Brussels, Belgium 5 Department of Nephrology, Clinique Universitaire Saint-Luc – Université Catholique de Louvain (UCLouvain), Brussels, Belgium 6 Department of Nephrology, Academisch Ziekenhuis (AZ) Groeninge, Kortrijk, Belgium 7 Department of Oncology, Academisch Ziekenhuis (AZ) Groeninge, Kortrijk, Belgium 8 Departement of Nephrology, Universitair Ziekenhuis (UZ) Antwerpen, Antwerpen, Belgium 9 Department of Oncology, GasthuisZuster, Antwerpen, Belgium 10 Department of Nephrology, Universitair Ziekenhuis (UZ) Leuven – Katholieke Universiteit Leuven (KUL), Leuven, Belgium 11 Department of Oncology, Universitair Ziekenhuis (UZ) Brussel – Vrije Universiteit Brussel (VUB), Brussels, Belgium

Approved by: Frontiers Editorial Office, Frontiers Media SA, Switzerland

*Correspondence: T. Van Meerhaeghe, tess.van.meerhaeghe@erasme.ulb.ac.be

This article was submitted to Onconephrology, a section of the journal Frontiers in Nephrology

 05 01 2023 2022 2 1129134 21 12 2022 22 12 2022 Copyright © 2023 Van Meerhaeghe, Baurain, Bechter, Orte Cano, Del Marmol, Devresse, Doubel, Hanssens, Hellemans, Lienard, Rutten, Sprangers, Le Moine and Aspeslagh 2023 Van Meerhaeghe, Baurain, Bechter, Orte Cano, Del Marmol, Devresse, Doubel, Hanssens, Hellemans, Lienard, Rutten, Sprangers, Le Moine and Aspeslagh

This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

 A corrigendum on Cemiplimab for advanced cutaneous squamous cell carcinoma in kidney transplant recipients by Van Meerhaeghe T, Baurain JF, Bechter O, Orte Cano C, Del Marmol V, Devresse A, Doubel P, Hanssens M, Hellemans R, Lienard D, Rutten A, Sprangers B, Le Moine A and Aspeslagh S (2022) Front. Nephrol. 2:1041819. doi: 10.3389/fneph.2022.1041819 cemiplimab kidney transplant recipients cutaneous squamous cell carcinoma immune checkpoint inhibitors rejection

In the published article, there was a mistake in the Funding statement. The following statement should be removed: “TM declares that this study received funding from Sanofi and Bristol Myers Squibb. The funders were not involved in the study design, collection, analysis, interpretation of data, the writing of this article or the decision to submit it for publication”. The correct statement appears below.

Funding

TM received research grants from Fonds Erasme, Fonds de la Chirurgie Cardiaque, le Fonds National de Recherche Scientifique Belgium (grant number 40010386), The Belgian Transplant Society Roche grant, The European Society of Organ Transplantation Transplant Fellowship.

The authors apologize for this error and state that this does not change the scientific conclusions of the article in any way.

 Publisher’s note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.